Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

TCGA-WA-A7H4-01A-21R-A34R-07

7a19e555-9a92-5e8a-86af-51d8b177e2e3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
sex
male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYOGENESIS+0.440
  • ANGIOGENESIS+0.270
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
  • HEDGEHOG_SIGNALING+0.160
  • COAGULATION+0.120
  • PANCREAS_BETA_CELLS+0.090
  • KRAS_SIGNALING_DN+0.060
  • KRAS_SIGNALING_UP+0.030
  • PROTEIN_SECRETION+0.030
  • UV_RESPONSE_DN+0.010

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.640
  • CHOLESTEROL_HOMEOSTASIS-0.570
  • INTERFERON_GAMMA_RESPONSE-0.560
  • MTORC1_SIGNALING-0.550
  • TNFA_SIGNALING_VIA_NFKB-0.540
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.530
  • MYC_TARGETS_V2-0.510
  • MYC_TARGETS_V1-0.470
  • E2F_TARGETS-0.440
  • HYPOXIA-0.440

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CN-4737-01A-01R-1436-07
head-neck@1
0.915
2e3d71c3f-4e56-45fa-be88-2cf444b70a5c
melanoma-umap@29
0.901
3SRR33346962
bladder-landscape@3
0.897
4SRR12202443
bladder-landscape@3
0.891
5MBCProject_0589_T1_RNA
breast-umap@18
A0.891
6SRR23303745
bladder-landscape@3
0.883
7SRR1516070
bladder-landscape@3
0.879
8TCGA-CQ-7072-01A-21R-A30B-07
head-neck@1
0.878
9SRR12696774
melanoma-umap@29
0.878
10SRR1335254
brain-umap@2
GTEX0.874

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYOGENESIS0.440Inavolisib— uncovered
ANGIOGENESIS0.270Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
HEDGEHOG_SIGNALING0.160Inavolisib— uncovered
COAGULATION0.120Binimetinib— uncovered
PANCREAS_BETA_CELLS0.090Cobimetinib— uncovered
KRAS_SIGNALING_DN0.060Remibrutinib— uncovered
KRAS_SIGNALING_UP0.030Inavolisib— uncovered
PROTEIN_SECRETION0.030Remibrutinib— uncovered
UV_RESPONSE_DN0.010Inavolisib— uncovered